VivaLNK has announced the results of a survey of pharma, biotech, and clinical research professionals on their opinions about the current state of remote patient monitoring (RPM). Findings unveil significant growth and advancement of RPM technologies throughout the course of the COVID-19 pandemic.
The survey reveals that nearly half (44%) have already adopted RPM for decentralized clinical trials or have plans to within the next 12 months. The adoption of remote monitoring during trials stems largely from COVID-19, as 65% of respondents noted concerns related to the pandemic as their primary driver for using RPM technology.
For more of the survey’s findings, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.